News & Resources

Events

Special Guidance on DEA’s COVID-19 Response Concerning the Production of Controlled Substance Medications

Eastern
American Conference Institute

Webinar Only

As the global pandemic progresses, the Diversion Control Division has been assuring the public that there is an adequate supply of controlled substances in the U.S., while also preventing the diversion of these controlled substances.

Hunter DeKoninck participated in the webinar "Special Guidance on DEA's COVID-19 Response Concerning the Production of Controlled Substance Medications" on Wednesday, June 3. The webinar reviewed the DEA's COVID-19 responses, identified challenges for suspicious order monitoring during the global pandemic and how to overcome due diligence road blocks while social distancing. 

We have updated our Privacy Policy. Please click here to view our new policy.